Dr. Reddy's Laboratories (NYSE: RDY) reported earnings on Feb. 3. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q3), Dr. Reddy's Laboratories beat expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share increased significantly.

Margins increased across the board.

Revenue details
Dr. Reddy's Laboratories reported revenue of $521.9 million. The five analysts polled by S&P Capital IQ predicted sales of $496.2 million. Sales were 23% higher than the prior-year quarter's $425.6 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.

EPS details
Non-GAAP EPS came in at $0.56. The one earnings estimate compiled by S&P Capital IQ averaged $0.50 per share on the same basis. GAAP EPS of $0.57 for Q3 were 58% higher than the prior-year quarter's $0.36 per share.

Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 59.9%, 500 basis points better than the prior-year quarter. Operating margin was 27.3%, 1,140 basis points better than the prior-year quarter. Net margin was 18.5%, 410 basis points better than the prior-year quarter.

Looking ahead
On the bottom line, the average EPS estimate is $0.61.

Next year's average estimate for revenue is $1.86 billion. The average EPS estimate is $1.72.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 514 members out of 541 rating the stock outperform, and 27 members rating it underperform. Among 146 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 142 give Dr. Reddy's Laboratories a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Dr. Reddy's Laboratories is outperform, with an average price target of $34.48.

The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Dr. Reddy's Laboratories the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.